TGF-beta in CAF-mediated tumor growth and metastasis
Abstract
TGF-beta signaling is one of the major pathways controlling cell and tissue behavior not only in homeostasis but also in disease. During tumorigenesis TGF-beta orchestrated processes are key due to its dual role as tumor suppressor and tumor promoter. Important functions of this pathway have been described in a context-dependent manner both in epithelial cancer cells and in the tumor microenvironment during tumor progression. Carcinoma-associated fibroblasts (CAFs) are one of the most abundant stromal cell types in virtually all solid tumors. CAFs favor malignant progression by providing cancer cells with proliferative, migratory, survival and invasive capacities. A complex network of signaling pathways underlying their tumor-promoting properties is beginning to take shape. In this review, we examine current evidence on the emerging mechanisms involving TGF-beta in CAF-mediated cancer progression, and discuss their potential as therapeutic targets.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activated fibroblasts and myofibroblasts abundantly secrete various ECM proteins, and matrix metalloproteases, cathepsins and other ECM remodeling enzymes.
“Indeed, activated fibroblasts and myofibroblasts abundantly secrete various ECM proteins, and matrix metalloproteases, cathepsins and other ECM remodeling enzymes77,224,235,236.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [236]
The citation lists haven’t been fetched yet
References 138 · Cited by 342
- Authors
- Calon, A., Tauriello, D. V. F., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Calon, A.
- Batlle, E.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 25
- Pages
- 15-22
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2027260842
- Cited by
- 342
- References
- 138
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 18 · 2023: 35 · 2022: 35 · 2021: 51 · 2020: 46 · 2019: 31 · 2018: 23 · 2017: 15 · 2016: 30 · 2015: 13 · 2014: 7
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Cancer Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministerio de Ciencia e Innovación
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- TGF-beta signaling, cancer-associated fibroblasts, tumor microenvironment, tumor growth, metastasis, tumor progression, tumor stroma, tumor invasion, tumor cell migration, therapeutic target
- MeSH terms
- Animals, Fibroblasts, Humans, Neoplasm Metastasis, Neoplasms, Signal Transduction, Transforming Growth Factor beta, Paracrine Communication, Tumor Burden, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
